Cargando…

Changes in immune profile affect disease progression in hepatocellular carcinoma

Objective: Hepatocellular carcinoma (HCC) as a chronic liver condition is largely associated with immune responses. Previous studies have revealed that different subsets of lymphocytes play fundamental roles in controlling or improving the development and outcome of solid tumors like HCC. Hence, thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fathi, Farshid, Saidi, Reza F, Banafshe, Hamid Reza, Arbabi, Mohsen, Lotfinia, Majid, Motedayyen, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891922/
https://www.ncbi.nlm.nih.gov/pubmed/35226515
http://dx.doi.org/10.1177/03946320221078476
_version_ 1784662015960154112
author Fathi, Farshid
Saidi, Reza F
Banafshe, Hamid Reza
Arbabi, Mohsen
Lotfinia, Majid
Motedayyen, Hossein
author_facet Fathi, Farshid
Saidi, Reza F
Banafshe, Hamid Reza
Arbabi, Mohsen
Lotfinia, Majid
Motedayyen, Hossein
author_sort Fathi, Farshid
collection PubMed
description Objective: Hepatocellular carcinoma (HCC) as a chronic liver condition is largely associated with immune responses. Previous studies have revealed that different subsets of lymphocytes play fundamental roles in controlling or improving the development and outcome of solid tumors like HCC. Hence, this study aimed to investigate whether immune system changes were related to disease development in HCC patients. Methods: Peripheral blood mononuclear cells were isolated from 30 HCC patients and 30 healthy volunteers using Ficoll density centrifugation. The isolated cells were stained with different primary antibodies and percentages of different immune cells were determined by flow cytometry. Results: HCC patients indicated significant reductions in the numbers of CD4(+) cells, Tbet+IFNγ+cells, and GATA+IL-4+cells in peripheral blood in comparison with healthy individuals (p < 0.05). There was no significant change in IL-17+RORγt+cells between patient and healthy groups. In contrast, Foxp3+CD127(low)cell frequency was significantly higher in patients than healthy subjects (p < 0.0001). The numbers of Th1, Th2, and Th17 cells were significantly lower in HCC patients than healthy control (p < 0.0001), although the reduction in Th2 cell numbers was not statistically significant. On the contrary, Treg percentage showed a significant increase in patients compared to healthy subjects (p < 0.0001). Other data revealed that Th1, Th2, and Th17 cell frequencies were significantly higher in healthy individuals than patients with different TNM stages of HCC, with the exception of Th2 in patients with stage II HCC (p < 0.01–0.05). Treg percentage was significantly increased in patients with different TNM stages (p < 0.0001). Among all CD4(+) T cells, the frequency of Th2 cell was significantly associated with TNM stages of HCC (p < 0.05). Conclusion: Our data provide further evidence to show that immune changes may participate in determining HCC progression and disease outcome. However, it should be mentioned that more investigations are needed to clarify our results and explain possible impacts of other immune cells on the pathogenesis of HCC.
format Online
Article
Text
id pubmed-8891922
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-88919222022-03-04 Changes in immune profile affect disease progression in hepatocellular carcinoma Fathi, Farshid Saidi, Reza F Banafshe, Hamid Reza Arbabi, Mohsen Lotfinia, Majid Motedayyen, Hossein Int J Immunopathol Pharmacol Original Research Article Objective: Hepatocellular carcinoma (HCC) as a chronic liver condition is largely associated with immune responses. Previous studies have revealed that different subsets of lymphocytes play fundamental roles in controlling or improving the development and outcome of solid tumors like HCC. Hence, this study aimed to investigate whether immune system changes were related to disease development in HCC patients. Methods: Peripheral blood mononuclear cells were isolated from 30 HCC patients and 30 healthy volunteers using Ficoll density centrifugation. The isolated cells were stained with different primary antibodies and percentages of different immune cells were determined by flow cytometry. Results: HCC patients indicated significant reductions in the numbers of CD4(+) cells, Tbet+IFNγ+cells, and GATA+IL-4+cells in peripheral blood in comparison with healthy individuals (p < 0.05). There was no significant change in IL-17+RORγt+cells between patient and healthy groups. In contrast, Foxp3+CD127(low)cell frequency was significantly higher in patients than healthy subjects (p < 0.0001). The numbers of Th1, Th2, and Th17 cells were significantly lower in HCC patients than healthy control (p < 0.0001), although the reduction in Th2 cell numbers was not statistically significant. On the contrary, Treg percentage showed a significant increase in patients compared to healthy subjects (p < 0.0001). Other data revealed that Th1, Th2, and Th17 cell frequencies were significantly higher in healthy individuals than patients with different TNM stages of HCC, with the exception of Th2 in patients with stage II HCC (p < 0.01–0.05). Treg percentage was significantly increased in patients with different TNM stages (p < 0.0001). Among all CD4(+) T cells, the frequency of Th2 cell was significantly associated with TNM stages of HCC (p < 0.05). Conclusion: Our data provide further evidence to show that immune changes may participate in determining HCC progression and disease outcome. However, it should be mentioned that more investigations are needed to clarify our results and explain possible impacts of other immune cells on the pathogenesis of HCC. SAGE Publications 2022-02-28 /pmc/articles/PMC8891922/ /pubmed/35226515 http://dx.doi.org/10.1177/03946320221078476 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Fathi, Farshid
Saidi, Reza F
Banafshe, Hamid Reza
Arbabi, Mohsen
Lotfinia, Majid
Motedayyen, Hossein
Changes in immune profile affect disease progression in hepatocellular carcinoma
title Changes in immune profile affect disease progression in hepatocellular carcinoma
title_full Changes in immune profile affect disease progression in hepatocellular carcinoma
title_fullStr Changes in immune profile affect disease progression in hepatocellular carcinoma
title_full_unstemmed Changes in immune profile affect disease progression in hepatocellular carcinoma
title_short Changes in immune profile affect disease progression in hepatocellular carcinoma
title_sort changes in immune profile affect disease progression in hepatocellular carcinoma
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891922/
https://www.ncbi.nlm.nih.gov/pubmed/35226515
http://dx.doi.org/10.1177/03946320221078476
work_keys_str_mv AT fathifarshid changesinimmuneprofileaffectdiseaseprogressioninhepatocellularcarcinoma
AT saidirezaf changesinimmuneprofileaffectdiseaseprogressioninhepatocellularcarcinoma
AT banafshehamidreza changesinimmuneprofileaffectdiseaseprogressioninhepatocellularcarcinoma
AT arbabimohsen changesinimmuneprofileaffectdiseaseprogressioninhepatocellularcarcinoma
AT lotfiniamajid changesinimmuneprofileaffectdiseaseprogressioninhepatocellularcarcinoma
AT motedayyenhossein changesinimmuneprofileaffectdiseaseprogressioninhepatocellularcarcinoma